Advanced search
Publication Cover
Expert Review of Ophthalmology Volume 8, 2013 - Issue 3
Submit an article Journal homepage
311
Views
1
CrossRef citations to date
0
Altmetric
Drug Profile

Intravitreal aflibercept use in the treatment of macular edema from central retinal vein occlusion

Michelle V Carle Retina-Vitreous Associates Medical Group, 1127 Wilshire Blvd, Suite 1620, Los Angeles, CA 90017, USA
,
Thomas G Chu Retina-Vitreous Associates Medical Group, 1127 Wilshire Blvd, Suite 1620, Los Angeles, CA 90017, USA
,
Homayoun Tabandeh Retina-Vitreous Associates Medical Group, 1127 Wilshire Blvd, Suite 1620, Los Angeles, CA 90017, USA
&
David S Boyer Retina-Vitreous Associates Medical Group, 1127 Wilshire Blvd, Suite 1620, Los Angeles, CA 90017, USA. [email protected]
Pages 227-235 | Published online: 09 Jan 2014

References

  • Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch. Ophthalmol. 126(4), 513–518 (2008).
  • Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch. Ophthalmol. 114(10), 1243–1247 (1996).
  • Wong TY, Larsen EK, Klein R et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 112(4), 540–547 (2005).
  • Rogers S, McIntosh RL, Cheung N et al.; International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(2), 313.e1–319.e1 (2010).
  • Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology 118(1), 119.e1–133.e1 (2011).
  • Mruthyunjaya P, Fekrat S. Central retinal vein occlusion. In: Retina (4th Edition). Ryan SJ (Ed.). Elsevier, PA, USA, 1339–1348 (2009).
  • Wong TY, Scott IU. Clinical practice. Retinal-vein occlusion. N. Engl. J. Med. 363(22), 2135–2144 (2010).
  • Morley MG, Heier JS. Venous obstructive disease of the retina. In: Ophthalmology. (3rd Edition). Yanoff M, Duker JS (Eds). Mosby, Inc., MO, USA, 597–601 (2008).
  • Sanborn GE, Magragal LE. Venous occlusive disease of the retina. In: Duane’s Ophthalmology on CD-ROM (2006 Edition). Lippincott Williams & Wilkins, PA, USA (2013).
  • Hayreh SS. Central retinal vein occlusion. In: The Retina and Its Disorders. Besharse JC, Bok D (Eds). Elsevier, CA, USA (2011).
  • McIntosh RL, Rogers SL, Lim L et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6), 1113.e15–1123.e15 (2010).
  • Decroos FC, Fekrat S. The natural history of retinal vein occlusion: what do we really know? Am. J. Ophthalmol. 151(5), 739.e2–741.e2 (2011).
  • Campochiaro PA, Hafiz G, Shah SM et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol. Ther. 16(4), 791–799 (2008).
  • Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion – results of a prospective case series. Graefes Arch. Clin. Exp. Ophthalmol. 245(10), 1429–1436 (2007).
  • Spaide RF, Chang LK, Klancnik JM et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am. J. Ophthalmol. 147(2), 298–306 (2009).
  • Campochiaro PA, Choy DF, Do DV et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 116(11), 2158–2164 (2009).
  • Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331(22), 1480–1487 (1994).
  • Funk M, Karl D, Georgopoulos M et al. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 116(12), 2393–2399 (2009).
  • Tong JP, Chan WM, Liu DT et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am. J. Ophthalmol. 141(3), 456–462 (2006).
  • The Central Retinal Vein Occlusion Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report. Ophthalmology 102(10), 1425–1433 (1995).
  • The Central Retinal Vein Occlusion Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report. Ophthalmology 102(10), 1434–1444 (1995).
  • SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch. Ophthalmol. 127, 1115–1128 (2009).
  • SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 5. Arch. Ophthalmol. 127, 1101–1114 (2009).
  • Brown DM, Campochiaro PA, Singh RP et al.; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117(6), 1124.e1–1133.e1 (2010).
  • Priglinger SG, Wolf AH, Kreutzer TC et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina (Philadelphia, PA) 27(8), 1004–1012 (2007).
  • Aggermann T, Brunner S, Krebs I et al.; ROVO Study Group. A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) study group. Graefes Arch. Clin. Exp. Ophthalmol. 251(4), 1065–1072 (2013).
  • Haller JA, Bandello F, Belfort R Jr et al.; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6), 1134.e3–1146.e3 (2010).
  • Kuppermann BD, Blumenkranz MS, Haller JA et al.; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. 125(3), 309–317 (2007).
  • Haller JA, Bandello F, Belfort R Jr et al.; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 118(12), 2453–2460 (2011).
  • Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg. Lasers Imaging 36(4), 336–339 (2005).
  • Holz FG, Ogura Y, Roider J et al. Intravitreal aflibercept injection for macular edema in central retinal vein occlusion: 1-year results of the Phase 3 GALILEO Study. Presented at: 2012 ARVO Annual Meeting. Fort Lauderdale, FL, USA, 6–9 May 2012 (Poster 6929).
  • Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am. J. Ophthalmol. 154(2), 222–226 (2012).
  • Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Philadelphia, PA) 26(8), 859–870 (2006).
  • Papadopoulos N, Martin J, Ruan Q et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15(2), 171–185 (2012).
  • Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99(17), 11393–11398 (2002).
  • CATT research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two year results. Ophthalmology 119, 1388–1398 (2012).
  • Cheung E, Myers K, Yancopoulos GD, Lobov IB, Wiegand SJ. Placental growth factor (PlGF)-deficient mice show delays in normal retinal vascular development and reduced vascular abnormalities in oxygen-induced retinal ischemia. Presented at: 2009 ARVO Annual Meeting. Fort Lauderdale, FL, USA, 3–7 May 2009 (Poster A462).
  • Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5(2), 123–132 (2006).
  • Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br. J. Ophthalmol. 92(5), 667–668 (2008).
  • Davidovic SP, Nokolic SV, Curic NH et al. Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy. Eur J. Ophthal. 22(5), 792–798 (2012).
  • Rudge JS, Holash J, Hylton D et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc. Natl Acad. Sci. USA 104(47), 18363–18370 (2007).
  • Heier JS, Brown DM, Chong V et al.; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119(12), 2537–2548 (2012).
  • Boyer D, Heier J, Brown DM et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the Phase 3 COPERNICUS study. Ophthalmology 119(5), 1024–1032 (2012).
  • Do DV, Nguyen QD, Boyer D et al.; DAVINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119(8), 1658–1665 (2012).
  • Holz FG, Roider J, Ogura Y et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the Phase III GALILEO study. Br. J. Ophthalmol. 97(3), 278–284 (2013).
  • Brown DM, for the COPERNICUS Study Investigators. Intravitreal aflibercept injection of central retinal vein occlusions: 2-year results from the COPERNICUS Study. Am. Acad. Ophthal. 155(3), 429–437 (2012).
  • Heier JS, Campochiaro PA, Yau L et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 119(4), 802–809 (2012).
  • Saichin Y, Saichin Y, Takahashi K et al. VEGF-Trap R1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood–retinal carrier. J. Cell Physiol. 195(2), 241–248 (2003).
  • Cao J, Zhao L, Li Y et al. A subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF Trap. Invest. Ophthalmol. Vis. Sci. 51(11), 6009–6017 (2010).
  • Heier JS, Boyer D, Nguyen QD et al.; CLEAR-IT 2 Investigators. The 1-year results of CLEAR-IT 2, a Phase 2 study of vascular endothelial growth factor Trap-Eye dosed as-needed after 12-week fixed dosing. Ophthalmology 118(6), 1098–1106 (2011).
  • Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin. Med. Insights. Oncol. 6, 19–30 (2012).
  • Nguyen QD, Shah SM, Hafiz G et al.; CLEAR-AMD 1 Study Group. A Phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113(9), 1522.e1–1522.e14 (2006).
  • Nguyen QD, Heier J, Brown D et al. Randomized, double-masked, active-controlled Phase 3 trial of the efficacy and safety of intravitreal VEGF Trap-Eye in wet AMD: one-year results of the View-1 study. Presented at: 2011 ARVO Annual Meeting. Fort Lauderdale, FL, USA, 1–5 May 2011 (Abstract 3073).
  • Schmidt-Erfurth U, Chong V, Kirchof B et al. Primary results of an international Phase III study using intravitreal VEGF Trap-Eye compared to ranibizumab in patients with wet AMD (VIEW 2). Presented at: 2011 ARVO Annual Meeting. Fort Lauderdale, FL, USA, 1–5 May 2011 (Abstract 1650).
  • Hahn P, Fekrat S. Aflibercept for central retinal vein occlusion: an ongoing revolution or are we spinning in place? Am. J. Ophthalmol. 155(3), 415.e2–417.e2 (2013).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.